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Abstract
Background: Carbapenems resistance in Enterobacter spp. has increased in the last decade, few studies, however,
described the mechanisms of resistance in this bacterium. This study evaluated clonality and mechanisms of
carbapenems resistance in clinical isolates of Enterobacter spp. identified in three hospitals in Brazil (Hospital A, B
and C) over 7-year.
Methods: Antibiotics sensitivity, pulsed-field gel electrophoresis (PFGE), PCR for carbapenemase and efflux pump
genes were performed for all carbapenems-resistant isolates. Outer-membrane protein (OMP) was evaluated based
on PFGE profile.
Results: A total of 130 isolates of Enterobacter spp were analyzed, 44/105 (41, 9%) E. aerogenes and 8/25 (32,0%) E.
cloacae were resistant to carbapenems. All isolates were susceptible to fosfomycin, polymyxin B and tigecycline.
KPC was present in 88.6% of E. aerogenes and in all E. cloacae resistant to carbapenems. The carbapenems-resistant
E. aerogenes identified in hospital A belonged to six clones, however, a predominant clone was identified in this
hospital over the study period. There is a predominant clone in Hospital B and Hospital C as well. The mechanisms
of resistance to carbapenems differ among subtypes. Most of the isolates co-harbored blaKPC, blaTEM and /or
blaCTX associated with decreased or lost of 35–36KDa and or 39 KDa OMP. The efflux pump AcrAB-TolC gene was
only identified in carbapenems-resistant E. cloacae.
Conclusions: There was a predominant clone in each hospital suggesting that cross-transmission of carbapenems-
resistant Enterobacter spp. was frequent. The isolates presented multiple mechanisms of resistance to carbapenems
including OMP alteration.
Keyword: E. aerogenes, E. cloacae, Resistance, Carbapenems, Efflux Pump, Outer Membrane Proteins, β-lactamases
and Activity efflux pump with inhibitor Carbonyl-cyanide-m-chlorophenylhydrazone (CCCP)
Background
Healthcare associated infections caused by Enterobacter
spp. have increased in the last decade all over the world
[1, 2]. Carbapenems are frequently used to treat serious
infections caused by multi-resistant Gram-negative bacilli,
especially those caused by over production of AmpC
cephalosporinases or extended-spectrum β-lactamases
(ESBL), such as infections caused by Enterobacter spp.
Thus, the emergence of carbapenems resistance, defined
as resistance to ertapenem, imipenem and/or meropenem,
is becoming a therapeutic challenge [1, 2].
To date, carbapenemase is the most frequent mechan-
ism of carbapenems resistance reported in Enterobacter
spp [2, 3]. Studies have shown the presence of carbape-
nameses (blaKPC, blaIMP, blaVIM and blaNDM) in
association with ESBL (blaTEM, blaSHV and blaCTX-
M) in isolates of E. aerogenes and E. cloacae resistant to
carbapenems [2, 3]. Although, E. aerogenes and E.
cloacae carbapenems-resistant isolates can decrease and
or loss OmpK 35–36 and 39KDa outer membrane pro-
teins (OMPs), which lead to alteration of permeability
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and the induction of active drug efflux AcrAB-tolc, that
contribute to resistance to carbapenems [2–6]. However,
few studies demonstrated the importance of OMPs and
efflux pump on carbapenems resistance in Enterobacter
spp [1, 2, 7].
Therefore, the role of mechanisms of carbapenems re-
sistance, such as OMP and efflux pump in Enterobacter
spp, needs to be better addressed. The present study was
conducted to investigate the clonality and mechanisms
of carbapenems resistance in E. aerogenes and E. cloacae
identified in three hospitals in Brazil.
Methods
Bacteria collection
One hundred and thirty Enterobacter spp. clinical iso-
lates (105 E. aerogenes and 25 E. cloacae) identified in
two hospitals (Hospital A and Hospital B whit 30 km of
distance between them) in São Paulo in the state of São
Paulo, and one hospital (Hospital C) 530 km distant, in
Londrina in the state of Paraná, Brazil, were evaluated
over a 7-year period, from 2005 to 2011.
Although, located in another state, the strains of E.
cloacae identified in Hospital C in Londrina were
evaluated in order to investigate the mechanism of carba-
penems resistance and clonality in this species as well.
The identification of species was performed by API20
E (bioMérieux, France) and additional tests (Modify
Rugai, Motility and Lysine).
Clinical data
The following clinical and demographic data from the
medical records of patients hospitalized in Hospital A
and Hospital B, were registered: age, gender, underlying
diseases, site of infection, length of stay in the Intensive
Care Unit and death. Definitions (CDC) for the infec-
tions were those used by the Centers for Disease Control
and Prevention. An Epi Info™ database was built, and
results were expressed as means (standard deviation) or
median (interquartile range), depending on normality.
All data were analyzed anonymously and confidentially,
with approval by the Research Ethics Committee of the
three hospitals.
Ethics statement
The study was performed in two hospitals located in São
Paulo, Brazil, the Central Institute of Hospital das
Clínicas of University of São Paulo (ICHC-FMUSP) and
Hospital Itapecerica da Serra and one hospital in Paraná,
the Universitary Hospital in Londrina. It was approved
by the ethics committee of the hospitals. The approval
number is 007/11.
Susceptible testing
The minimal inhibitory concentrations (MICs) of imipe-
nem (Merck & Co. Inc., Elkton, EUA), meropenem (Astra
Zeneca), ertapenem (Sigma Chemical, St. Louis, Mo.),
cefepime (Bristol-Myers Squibb, Guayaquil, Equador),
polymyxin B (Sigma Chemical, St. Louis, Mo.) and tige-
cycline (Sigma Chemical, St. Louis, Mo.), was performed
by broth microdilution with Mueller-Hinton broth. In
addition, the MIC of fosfomycin (Sigma Chemical, St.
Louis, Mo.) was performed using agar dilution as de-
scribed in Clinical and Laboratory Standards Institute
(CLSI). P. aeruginosa ATCC 27853, E. coli ATTC 25922,
S. aureus ATCC 29213 and E. faecalis ATCC 29212, were
used as control for all isolates (105 E. aerogenes and 25 E.
cloacae). Carbapenems resistance was defined as: resist-
ance to one or more carbepenems (ertapenem, imipenem
and or meropenem) according with CLSI breakpoint.
Carbapenemase genes and efflux pump
The presence of genes encoding ESBL (blaTEM, blaSHV,
blaCTX-M), carbapenemases Class A (blaKPC, blaIMI
and blaGES), Class B (blaIMP-1, blaVIM-2, blaGIM −1,
blaSPM, blaNDM-1) and Class D (blaOXA-48), was
investigated in all isolates (105 E. aerogenes and 25 E.
cloacae) by PCR as described elsewhere (Table 1) [8–11],
genbanks accession numbers: KF285575-KF285585,
KY524253 and MTZP00000000.
PCR for all isolates (105 E. aerogenes and 25 E. cloacae)
was performed to detect genes of efflux pump acrART
using primers according to the study of Perez et al. [12].
DNA sequencing of genes of resistance was performed
using the MegaBACE 1000, DNA Analysis System
(Amersham Biosciences, UK. England), using DYEnamic
ET Dye Terminator Kit (with Thermo Sequence™ DNA
Polymerase II) US81090 code. The sequences were
analyzed using the Sequence Analyzer software using the
Cimarron Base Caller 3.12. The genetic sequence was
compared with the database available on the Internet
(BLAST - http://www.ncbi.nlm.nhi.gov/blast/).
Pulsed-field gel electrophoresis
DNA analysis of all carbapenems-resistant isolates, 44 E.
aerogenes and 8 E. cloacae were performed by PFGE, after
digestion with XbaI Fast (Invitrogen) and the electrophor-
etic run was made with the following parameters: 23 h with
pulse times ranging from 5 to 60s at 6 V/cm, using the
CHEF-DR III System (Bio-Rad Laboratories, Richmond,
CA, USA). DNA relatedness was computationally analyzed
using BioNumerics v.7.1 software (Applied Maths, Sint-
Martens-Latem, Belgium). The banding patterns were
compared by using the unweighted pair-group method with
arithmetic averages (UPGMA), with the Dice similarity
coefficient required to be >80% for the pattern to be con-
sidered as belonging to the same PFGE type (dendrogram).
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Outer membrane protein profile
Based on clonality, the OMP of 22 E. aerogenes isolates
and 5 E. cloacae isolates were analyzed. Bacterial outer
membrane proteins (OMPs) were purified by treatment of
the cell envelops with 2% sodium-N-lauryl sarcosinate
(Sigma Chemical.St Louis., MO). The proteins were quan-
tified by the Bradford method with the aid of Bradford re-
agent (Bio-Rad Laboratories, Brazil) by spectrophotometry
at 595 nm (GeneQuant Pro, GE- Healthcare Life Sciences)
and subsequently treated with beta-mercapto-ethanol at a
ratio of 2 μl acid beta-mercaptoethanol acid to 10 μl pro-
tein. The proteins studied were applied to polyacrylamide
gels prior manufactured 12.5% (GE Healthcare) at a con-
centration of 20 ng. Electrophoreses run was performed
on the Multiphor II device (SG) at 600 V, 50 mA, and
30 W for about 60 min. The following molecular weights
were used as markers: 97.4 KDa (phosphorylase B from rat
muscle), 66,2KDa (bovine serum albumin), 45 kDa (egg
albumin), 31,0KDa (bovine carbonic anhydrase), 21,51KDa
(trypsin inhibitor) and 14,4KDa (lysozyme). Enterobacter
aerogenes ATCC13048 was used as control. After electro-
phoresis, the gel was stained with Silver Staining Kit plus
one Kit, Protein (GE Healthcare) according to the manu-
facturer’s instructions. We classified the protein profile
based on intensity of band in without lack or loss of
protein (++++), very little reduction of protein (+++),
reduction (++), major reduction (+) and absent of protein
based on previously described by Mostachio et al. [13].
Efflux pump activity
The efflux pump activity was analyzed based on car-
bapenems’s MIC in 5 E. cloacae that harbored efflux
pump gene and 5 in E. aerogenes belonged to differ-
ent clones. MICs of imipenem, meropenem and erta-
penem with 50 and 100 mg/mL and without the
efflux pump inhibitors Carbonyl-cyanide-m-chlorophe-
nylhydrazone (CCCP-Sigma Chemical.St Louis., MO)
were determined by agar dilution to investigate the
role of efflux pump on carbapenems-resistant E. aerogenes
and E. cloacae isolates. The influence of an efflux pump
on the carbapenems’s MIC for a given bacterial strain was
determined by a reduction of at least four-fold of the
respective MIC in the presence of CCCP [2].
Results
A total of 44/105 (41, 9%) E. aerogenes and 8/25 (32,
0%) E. cloacae were resistant to carbapenems. Thirty-
nine isolates of E. aerogenes resistant to carbapenems
were identified in Hospital A, 5 isolates of E. aero-
genes in Hospital B and 8 isolates of E. cloacae in
Table 1 Primers of all carbapenems resistance genes studied and PCR annealing temperature
Primers Sequences (5′-3′) Annealing temperature Size (pb)
blaTEM - F TCGCCGCATACACTATTCTCAGAATGA 55 420
blaTEM - R ACG CTC ACC GGC TCC AGA TTT AT
blaCTXM - F GCT CTAGAATTATTGCATCAGAAA CCGTG 55 893
blaCTXM - R CGGAATTCATGATGACTCAGAGCATTGG
blaOSHV - F TGCTTTGTTAATTCGGGCCAA 55 730
blaSHV - R ATGCGTTATATTCGCCTGTG
blaOXA48 - F GTAACAATGCTTGGTTCG 55 177
blaOXA48 - R TGTTTTTGGTGGCATCGA
blakpc - F GTTACGCCAAAGGACGAAC 893
blakpc - R TTTTCAGAGCCTTACTGCCC
blaSPM -F CCTTTTCCGCGACCTTGATC 59 798
blaSPM - R ATGCGCTTCATTCACGCAC
blaSIM - F GTACAAGGGATTCGGCATCG 58 569
blaSIM - R GTACAAGGGATTCGGCATCG
blaIMP -F TTGGAAAATTATATAATCCC 47 188
blaIMP - R CCAAACCACTAGGTTATC
blaVIM - F TTTGGTCGCATATCGCAAAG 60 382
blaVIM- R CCATTCAGCCCAGATCGGCAT
blaNDM - F GGCGGAATGGCTCATCACGA 60 375
blaNDM - R CGCAACACAGCCTGACTTTC
AcrART - F GAT TAT GAT TCT GCC TTG GCCG 60 130
AcrART - R CAA TGC GAC CGC TGA TAG GGG
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Hospital C. E. aerogenes isolates presented MIC ran-
ging from 2 to 128 mg /ml for imipenem, 4 to 64 mg
/ml for meropenem and 1 to ≥128 mg /mL for erta-
penem. E. cloacae isolates showed MIC ranging from
8 to 64 mg/ml for imipenem, 2 to 16 mg / ml for
meropenem and 8 to 64 mg/mL for ertapenem. All
isolates were susceptible to fosfomycin, polymyxin B
and tigecycline (Table 2).
Demographic and clinical data of 39 patients with
colonization and infection caused by E. aerogenes re-
sistant to carbapenems in Hospital A and 5 in hos-
pital B are shown in Table 2. Most of the isolates
were from blood 12 (30.8%), followed by 9 (23%)
from respiratory tract secretion and 6 (15.4%) from
urine. Most of patients (N = 17) undergone surgery (4
liver and 2 kidney transplant), 2 patients received
chemotherapy (1 acute leukemia and 1 bone marrow
transplant) and 1 patient was HIV positive (Table 3).
There was no clinical information regarding isolates
identified in Hospital C, although, all isolates were
from surveillance swabs.
The PCR showed that 39/44 (88.6%) E. aerogenes
isolates harbored blaKPC, other genes encoding carba-
penemases were not identified in any isolate. Thirty-
nine (88.6%) had blaTEM-1 gene and 41 (93.2%)
blaCTX-M gene. Among the eight isolates of E. clo-
acae, all harbored blaKPC and blaTEM-1 genes; other
carbapenemases studied were not identified.
The outer membrane proteins of 22 of the 44 isolates
of E. aerogenes and 5 of 8 isolates of E. cloacae were
analyzed. The intensity of the proteins of interest Omp F
(39 KDa) OMP C (42 KDa), 35–36KDa were compared
with the molecular weight and ATCC E. aerogenes
13048 was used as control (Table 4).
Table 2 In vitro activity of 7 antibiotics against 44 E. aerogenes and 8 E. cloacae carbapenems-resistant strains isolated in three
Brazilians hospitals using microdilution and agar dilution
Antibiotics Range CIM 50 (mg/mL) CIM 90 (mg/mL) % resistance CIM 50 (mg/mL) CIM 90 (mg/mL) % resistance
Imipenem 0,25–128 8 32 93,2 16 64 100
Meropenem 0,25–128 8 32 93,2 16 16 87,5
Ertapenem 0,25–128 64 128 86,4 64 64 100
Tigecycline 0,03–16 0,25 2 0 1 2 0
Fosfomycina 0,25–256 16 64 0 16 32 0
Polymyxin B 0,003–16 1 2 0 1 2 0
Cefepime 0,25–128 ≥128 ≥128 100 ≥128 ≥128 100
aMIC by agar dilution
Table 3 Clinical and demographic characteristics of 39 patients with infection and colonization caused by carbapenems-resistant E.
aerogenes from Hospital A and 5 patients with colonization and infection caused by carbapenems-resistant E. aerogenes from Hospital B
Patients variables Hospital A
N = 39 (%)
Hospital B
N = 5 (%)
Age ( range), mean 18–87 years old , 55.6 years old 24–88 years old, ,58.2 years old
Gender
Female 13 (33,3%) 0
Male 22 (56,4%) 5 (100%)
Length of stay before identification of E. aerogenes (range), mean 6–190 days, 43.7 days 9–17 days, 16.2 days
Site of isolation
Blood 12 (30,8%) 1 (20%)
Respiratory Tract secretiona 9 (23,1%) 0
Urine 6 (15,4%) 0
Peritoneal fluid 3 (8%) 0
Skin 2 (6%) 0
Others 7 (18%) 1 (20%)
Rectal swab 0 3 (60%)
Intensive care unit 23 (59%) 3 (60%)
Death 24 (61,5%) 1 (20%)
aTracheal secretion and Bronco alveolar lavage (BAL)
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The protein profile was classified based on intensity of
band in without lack or loss of protein (++++), very little
reduction of protein (+++), reduction (++), great reduction
(+) and absent (Table 4). All isolates resistant to carbapen-
ems in this study showed a decrease in 35–36 KDa protein.
We observed that the 42KDa protein in our analysis did
not appear to be involved in carbapenems resistance.
E. aerogenes isolates with decrease of 39 KDa pro-
tein, presented CIM of 2–128 mg/mL to imipenem,
4–64 mg/mL to meropenem and 8 a ≥128 mg/mL to
ertapenem. Isolates of E. aerogenes, which presented
absence of 39 KDa protein showed MIC of 8 to 32 mg/ml
for imipenem, 4 to 32 mg/ml for meropenem and
32–64 mg/mL to ertapenem.
E. aerogenes isolates with decrease of 35–36 KDa pro-
tein, presented MIC of 2–32 mg/ml for imipenem and 4
to 32 mg/ml for meropenem and 8–128 mg / mL to
ertapenem. E. aerogenes isolates with absence of the
protein of 35–36 KDa showed MIC of 128 mg/mL to
imipenem, 64 mg/mL to meropenem and ≥128 mg/mL
to ertapenem.
Moreover, all isolates of carbapenems-resistant E. clo-
acae showed decreased of 39KDa protein and absence
of 35–36 KDa protein and their MICs to imipenem
were 8 to 64 mg/ml, 2 to 16 mg/mL to meropenem and
8–64 mg/mL to ertapenem (Table 5).
The PFGE showed 6 clones (A, B, C, E, F and G) among
39 isolates of carbapenems-resistant E. aerogenes identi-
fied in Hospital A. Clone A was present only in the first
two year of study (2005 and 2006), and it was replaced by
clone C that circulated during the entirely study. Twenty-
seven (69.2%) isolates belonged to this predominant clone
C that harbored KPC, TEM-1 and CTXM, whose subtypes
ranging from C1 to C19 over the 7-year study period,
from 2005 to 2011 (Fig. 1). Two subtypes (C17 and C19)
of clone C and clone F were KPC negative.
The 4 carbapenems-resistant E. aerogenes identified in
Hospital B belonged to a predominant clone nominated
as clone D with subtypes from D1 to D3. This clone har-
bored KPC and TEM-1, and showed decreased of 39
and 35–36 KDa proteins (Fig. 1 and Table 5).
In addition, the 8 carbapenems-resistant E. cloacae iden-
tified in Hospital C in Londrina belonged to two clones,
clone A (predominant clone) and clone B (Fig. 2). All
carbapenems-resistant E. cloacae isolates harbored KPC,
TEM-1 and efflux pump gene acrART (Fig. 2). These
clones showed as well lost of 35–36KDa proteins (Table 5).
The efflux pump AcrAB-TolC gene was only identified
in carbapenems-resistant E. cloacae. All 5 isolates posi-
tive for this efflux pump were resistant to imipenem,
meropenem and ertapenem with MICs above 8 mg/mL
for all carbapenems (Tables 4 and 5).
The 5 carbapenems-resistant E. aerogenes isolates
belonged to different clones and showed efflux pump
activity in presence of CCCP inhibitor. Among the
carbapenems-resistant E. cloacae, 2 of the 5 isolates
showed efflux pump activity for meropenem, imipenem
and ertapenem, and 3 isolates showed no activity on
presence of ertapenem (Tables 4 and 5).
Discussion
In the present study, we demonstrated that all E. aero-
genes and E. cloacae isolates resistant to carbapenems
were susceptible to polymyxin B, tigecycline and fosfo-
mycin. KPC was the only carbapenemase identified. In
contrast with previous studies [5, 10, 14], most of
carbapenems-resistant E. aerogenes isolates co-harbored
KPC and wide spectrum ESBL, such as blaTEM and
blaCTX-M, in association with alteration of OMPs,
mainly reduction or loss of 35–36 KDa and 39KDa
proteins. In addition to alteration of OMPs, E. cloacae
isolates harbored blaKPC; blaTEM and efflux pump gene
acrART. E. aerogenes isolates were polyclonal, although
a different predominant clone was finding in each hos-
pital. On the other hand, E. cloacae belonged to two
clones. The mechanisms of resistance to carbapenems
Table 4 Minimum inhibitory concentration of carbapenems of 5 carbapenems-resistant E. aerogenes and 5 carbapenems-resistant E.
cloacae isolates by agar dilution with or without efflux inhibitor CCCP
Antimicrobial agent E. aerogenes (non-harboring acrART gene)
N = 5
E. cloacae (harboring acrART gene)
N = 5
50 mg/mL CCCP 100 mg/mL CCCP
MIC (mg/mL) SD MIC (mg/mL) SD
Imipenem 8 8 32 64 2 25,75 4 8 4 8 32 11,79
Imipenem + CCCP ≤0,125 ≤0,125 ≤0,125 ≤0,125 0,25 0 ≤0,125 ≤0,125 ≤0,125 ≤0,125 ≤0,125 0
Meropenem 4 4 8 32 8 11,79 4 4 2 8 16 5,58
Meropenem + CCCP ≤0,125 ≤0,125 1 ≤0,125 1 0 ≤0,125 ≤0,125 ≤0,125 ≤0,125 ≤0,125 0
Ertapenem 32 64 32 256 32 93,38 16 16 8 32 32 10,73
Ertapenem + CCCP ≤0,125 2 ≤0,125 2 4 1,61 8 8 ≤0,125 ≤0,125 ≤0,125 4,35
All isolates harbored KPC
SD standart deviation
Rosa et al. BMC Microbiology  (2017) 17:69 Page 5 of 9
differed among E. aerogenes subtypes. We identified
isolates of E. aerogenes resistant to carbapenems that
harbored only ESBL (TEM-1 and CTX-M) associated with
decreased or loss of 35–36 kDa and 39 kDa proteins.
E. aerogenes and E. cloacae are important agents of
healthcare-associated infections in several countries and
resistance to carbapenems has been increasing in the last
decade, thus there is a need for in vitro studies showing
alternatives for the treatment of infections due to these
microorganisms [3, 7, 14]. Since our susceptibility results
showed that all carbapenems-resistant isolates were
susceptible to tigecycline, fosfomycin, and polymyxin B,
we consider these findings quite promising. However, it
is noteworthy that despite the excellent results in vitro,
pharmacokinetics and pharmacodynamics of tigecycline
and fosfomycin, and the limited clinical experience in
serious infections, especially bloodstream infections, are
obstacles to the routine use of these antimicrobials
in the treatment of systemic infections. Despite of
these drawbacks, these drugs have been used with
success as combination therapy in the treatment of
severe infections caused by Enterobacteriaceae resistant to
carbapenems [15, 16].
The demographic and clinical data from the studied
hospitals showed that the most frequent site of isolation
of carbapenems-resistant Enterobacter was blood, most
of our patients had undergone surgical procedures, and
had a high overall mortality, similar to previous studies
[14, 17]. The only carbapenemase identified in our study
was KPC. Data regarding carbapenems resistance in
Enterobacter spp. in Brazil are scarce, although KPC is
the carbapenemase most often described in Enterobacter
spp. isolates in Brazilians hospitals [5, 7, 14].
Regarding the clonality, we identified in Hospital A, in
São Paulo, 6 clones of E. aerogenes, named A, B, C, E, F
and G over the study period, from 2005 to 2011, with
Table 5 Outer membrane proteins, blaKPC gene, blaTEM and blaCTX and pump efflux (AcrART) profile of 22 carbapenems-resistant
isolates of E. aerogenes (hospital A and B) and 5 E. cloacae (hospital C)
Imipenem Meropenem Ertapenem PCR SDS-PAGE
PFGE Hospital Date MIC MIC MIC bla KPC bla CTX bla TEM 1 acrART 42 KDa 39 Kda 35 e 36 KDa
A2 A 13/05/2005 32 8 32 + + + - ++++ +++ ++
A2 A 10/12/2005 16 8 64 + + + - ++++ +++ ++
C11 A 18/05/2006 32 16 128 + + + - ++++ +++ ++
C11 A 13/07/2006 32 16 128 + + + - ++++ ++++ ++
C8 A 14/07/2006 16 16 64 + + + - ++++ ++++ ++
C7 A 02/01/2007 16 4 32 + + + - ++++ Absent ++
C6 A 23/03/2007 16 8 64 + + + - ++++ +++ ++
C13 A 25/04/2007 8 4 32 + + + - +++ Absent ++
C14 A 21/09/2007 8 4 64 + + + - ++++ +++ ++
G1 A 10/11/2008 32 16 64 + - - - +++ Absent ++
C1 A 06/01/2009 16 32 64 + - + - +++ Absent ++
C2 A 31/08/2009 16 4 16 + + + - +++ ++ ++
C4 A 03/11/2009 32 16 64 + + + - +++ Absent ++
C5 A 29/11/2009 16 4 32 + + + - +++ + ++
C3 A 05/12/2009 4 4 16 + + + - +++ ++ ++
B1 A 16/03/2010 16 8 64 + + + - +++ Absent ++
F1 A 08/06/2011 128 64 ≥128 + - + - +++ ++ Absent
D2 B 26/12/2010 2 8 32 + + + - ++++ + ++
D1 B 05/01/2011 4 8 32 + + + - ++++ + ++
D1 B 05/01/2011 4 8 32 + + + - ++++ + ++
D3 B 06/01/2011 4 8 8 + + + - +++ + ++
A2 C 19/11/2012 8 2 8 + - + + +++ + Absent
B1 C - 8 8 64 + - + + +++ + Absent
B1 C - 8 8 64 + - + + +++ + Absent
A3 C - 64 16 64 + - + + +++ + Absent
A5 C - 16 16 64 + - + + +++ + Absent
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Fig. 1 Dendogram of 39 carbapenems-resistant E. aerogenes isolates from Hospital A and 5 carbapenems-resistant E aerogenes from Hospital B
Fig. 2 Dendrogram of 8 carbapenems-resistant E. cloacae isolates from Hospital C
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the predominance of clone C. One predominant clone
was also identified in hospital B in São Paulo. An intri-
guing finding is that one isolate of hospital B seems to
be related to a clone of hospital A, pointed to a possible
inter-hospital spread. Two clones A (subtypes A1 to A5)
and B were identified among E. cloacae isolates resistant
to carbapenems in Hospital C, in Londrina, Paraná.
These findings suggest that cross-transmissions have
occurred over the study period in all hospitals and high-
light the importance of the stringent enforcement of
hand hygiene and contact precautions to control the
spread of this agent. Another interesting finding is that
the mechanism of resistance to carbapenems in E. aero-
genes from hospital A differs among subtypes and CTX-M
was only identified in this hospital.
The profile of outer-membrane proteins of our
isolates demonstrated that all isolates studied showed
reduction of 35–36 KDa OMPs. These OMPs have been
associated with β-lactam resistance in Enterobacter spp
[18–21]. Studies in vivo and in vitro showed that
diminished or loss of these OPMS were associated with
increase on imipenem and meropenem MIC [18–22].
Other OMPs previously associated with carbapenems-
resistance among E. aerogenes are OMPs of 42KDa and
OMP of 39KDa [19]. However, in contrast with previ-
ous studies, we could not associate the alteration of the
42KDa OmpC with carbapenems resistance in our E.
aerogenes and E. cloacae isolates. This finding could be
explained perhaps by the clones that circulated in
Brazil. Data regarding OMP in carbapenems–resistant
Enterobacter in Brazil is limited. However, a previous
Brazilian study demonstrated that OmpC and OmpF
were present in only 6.6% of E. cloacae isolates resistant
to ertapenem [5].
Few authors had evaluated the role of efflux pump on
carbapenems resistance in Enterobacter spp [23, 24].
Efflux pump AcrAB system has been described as associ-
ated with resistance to meropenem and imipenem in E.
cloacae [2, 22, 23]. In carbapenems-resistant E. aerogenes
there were descriptions of efflux pump associated with
KPC and/or porin loss as well [2, 23, 24]. In our study,
the efflux pump AcrART was found only in E. cloacae.
However, eventhough E. aerogenes isolates did not
present the efflux pump AcrART gene, carbapenem ef-
flux pump activity was observed in the presence of
CCCP inhibitor. Possibly, these E. aerogenes isolates have
other efflux pump, not described yet. These findings
reinforce the importance of association of mechanism of
resistance in carbapenems-resistant Enterobacter spp.
This study has several limitations: besides being retro-
spective, we evaluated only three hospitals and we could ac-
cess the clinical data from only two hospitals. However, we
were able to demonstrate that there was an association of
mechanism of resistance such as β-lactamase, alteration of
outer-membrane protein and efflux pump in carbapenems-
resistant Enterobacter spp. in Brazil.
Conclusion
In conclusion, we observed that there was a predominant
clone in each hospital, suggesting that cross-transmission
of carbapenems-resistant Enterobacter spp. was frequent.
The isolates presented multiple mechanisms of resistance
to carbapenems, such as KPC, ESBL and alteration of the
outer membrane protein. E. cloacae presented as well the
efflux pump AcrART, and in vitro activity of efflux pump
inhibitor. These findings can be useful to control the
spread of carbapenems resistance among Enterobacter
spp. in the hospital setting.
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